lawsone

We are lawsone CAS:83-72-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:lawsone
CAS.NO:83-72-7
Synonyms:1,4-Naphthalenedione, 2-hydroxy-
 2-Hydroxy-p-naphthoquinone 
2-Hydroxy-1,4-naphoquinone;
 
Molecular Formula:C10H6O3
Molecular Weight:174.15300
 
Physical and Chemical Properties:
Density:1.46;
Melting point:192-195oC;
Boiling point:339.908oC;
 
Specification:
Appearance:Light yellow crystal
Purity(HPLC):≥99.0%
Ash:≤0.5%
Loss on drying:≤0.5%
Fe content:≤100ppm
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Hair dyes intermediate
 

lawsone


Related News: The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.5-Bromo-2-ethoxypyridine CAS:55849-30-4 The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.40161-54-4 The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.4286-55-9 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.

Related Products
Product Name
2-Propoxyethanol View Details
Pentachlorobenzonitrile View Details
5,6-dimethoxy-2,3-dihydroinden-1-one View Details
2,4,5-Trichloropyrimidine manufacturer 4-Bromo-3-(trifluoromethyl)phenol manufacturer N,N-dimethyl-3-oxobutanamide manufacturer dichloromethyl(triethoxy)silane manufacturer 2,4-Difluorobenzyl Alcohol manufacturer